>> i think it's time to add protection to the portfolio, especially if you have been long in the market here. certainly the runup, i like the zero cost calendar. >> it looks like our time is expired. check my mission is simple to make you money. i'm here to level the playing field for all investors. there is a bull market somewhere and i promise to help you find it "mad money" starts now. >> i'm cramer, welcome to "mad money." welcome to cramerica. other people want to make friends, i'm just trying to save you a little money. my job isn't just to entertain but to educate and teach you. call me or tweet me at jim cramer. we all know that great scene from "wall street" where michael douglas as gordon gecko made his famous pronouncement --

>> greed, for lack of a better word, is good. >> sorry, michael douglas. you're a good looking guy and fabulously a big fan of our show. but you're wrong. greed is bad. not good. we have such amazing gains here and you have to ask yourself if you've taken anything off the table yet. think about it. this has been a real good run. and even if you are as bullish as i am don't you have to think about ringing the register on something? on anything? with the idea that if the market reverses you'll have the cash to buy, buy, buy. i want you to just ponder it over the week. we took out a lot of highs today. dow up s&p 500 rockets, nasdaq up 0.7%. now look i am not saying i don't like it here. i think we have a right to run

after a big, bad event. you know i've been bullish as all get out, urging you to buy every one of these dips we' been having. i'm just saying when you see these kinds of monster moving going mighter, you have to remember there are going to be speed bumps. when we hit those speed bumps, you need to have enough cash on the sidelines that you can take advantage of them. or, are you going to be caught with your pants down having taken no profits at all? that's not the way we roll in cramerica. all right, a mild admonition in mind. i thought about it all day. let's see what's ahead for next week. first we know these days we need to see some china bounce just a little bounce please. even a teeny weeny one in order to validate the valuation of these stocks. the hsbc manufacturing bmi, we

need something north of 5.1, remember that. you need 5.1 in order to be able to make this thing tick. or else i suspect we will open down on monday morning. tuesday morning, giii which has beaten the numbers. mccorm mick the staple spice company, another good buy. but the one to buy is sonic, which i just reiterated on yesterday's show. it's part of the restaurant trade that started the moment gasoline went below $3 and only gained steam. unfortunately, sonic is also at its 52-week high which means while weit can still go up, we're hardly early. wednesday, we've been behind paychex, the payroll processing company that i'm a proud client of in the mid 30s and it's now at 51. there are so many analysts that don't care for the stock because they think the client base isn't growing fast enough and there's not enough money to be made on

the float the interest paychex can make on the cash they hold while you wait to get your cash from your check. i think some analysts break ranks and go positive on paychex after the quarter even as they sat out a pretty good move. they want to get ahead of a fed rate hike. also on wednesday, we have two companies disappointed cently and are being given a chance to redeem themselves. five below and pvh. i have a predisposition to like both company's stocks down here. but they're in the penalty box because of some bad misses and guide-downs. i know both are tempting aren't they? however, this market rewards winners and punishing losers endlessly. so we have to be in wait and see mode for both these two companies. thursday has a couple of real difficult ideas i want to puzzle over. the first is lulu lemon. this company has totally turned the corner which is why my charitable trust owns lulu

lemon. we have a big gain in lulu. but we're concerned about the california port slowdown that nike alluded to may have hurt this company. it hurt william sonoma badly. so it's possible it will dip. why not sell ahead? wait a second, because the port story is temporary, and who knows if you can be nimble enough to get out and back in again. unless you're a hedge fund manager you won't have the ability to time things that perfectly. in fact, i think it's an excellent buying opportunity as many short sellers seem to be betting against lulu precisely because of this well known port slowdown issue. it might make a solid moment to snatch some up if you get a chance. then we hear from gamestop. this is a very controversial stop. there's a monster short position. 44% of the float is short. that's insane. you can understand where the bears are coming from though. people who now download video games the way they down load all software. however, i think we might be working on a good trade idea

here. buy take 2 interactive off of gamestop's result. they've been hammered mercilessly. we've got to have a new data point to justify pulling the trigger. on february 10, take 2 unveiled a game called evolve. if we hear anything on this game stop about evolve we might have a terrific entry point to buy take 2 interactive off the gamestop conference call. next up blackberry reports on friday. gunners think there's no way this company won't be bought by someone, anyone. i have a problem with that theory. on "mad money" i never support buying a stock on a takeover. the blackberry fundamentals are not good enough to bank on. pass. speaking of weakening fundamentals, last quarter from finish line was nothing to write home about. it never came back or looked back. a gunner might want to buy call

option on the stock to protect themselves on the down side betting on if nike has a good one, finish line has to have a good one, too, right? nike reported that great number last night. but that didn't work last time and finish line is too dependent on nike as a supplier for me to buy ahead of the quarter. all week we'll keel an eye on europe. one reason we rallied is because the dollar got weaker. we've become convinced an conditioned to believe if the dollar gets stronger the entire stock market should go lower. so the flip side has become true, too. a weak dollar like today spurred by many companies, particularly the industrials. an amazing number of people are saying the dollar is still going to go higher and you know what i think it's going to go higher. but if we get signs from europe next week that things are getting better over there, the dollar is going to get slammed again some more and that could lead to another wave of rally for our stocks. i think much more of this rally may have been realize than we

even talked about. you know, germany and greece are making up, and that's what's cause pg the euro to get stronger. so keep an eye on europe all week for positive data. because europe, like it or not, still matters tremendously. so let me give you the bottom line. can this post federally continue? i don't see a lot of data in the way, and i do see some potentially positive earnings reports next week. nevertheless, what i'm saying is please don't get greedy. we tend to forget how terrible the market was a week ago. so please ring the register on something, raise a little cash because just for the record this market is about as good as it can get. and that alone makes me concerned about the complacency that i now feel does abound after that fed meaning freed the bulls and let them stampede the bears to close out a very strong week. adam in north carolina adam. >> caller: hey, jim. i watched you and want to know you inspired me to get my mba.

>> thank you. >> caller: thank you for the inspiration you provide to everyone out there. congratulations on ten years. >> you're terrific. thank you. >> caller: i know how you have on armon, but i want to know as what your thought is on auto lid in the car market. >> it's good. but you're right, i do like harmon. i also like leer. i think leer is good. but your stock is good. the parts companies are better than the actual auto companies. how about betsy in new york? petty. . >> caller: yes? >> hi. you're on. >> caller: this is betsy from quog. >> get out. did you go to the library book sign. >> caller: no, i didn't. i'm sorry. i didn't know it was happening. >> okay, all right. >> caller: i'm interested in nat, north american tankers. it's been going up, up, up, except for today. other pundits say sell sell, sell. and boy, buy more sell or hold. >> you've got a gun to my head.

all i keep thinking is i'll see you on the beach. nor dick america has has been a real bad stock. they do have the possibility of an increased dividend this year. there was insider buy, a large amount of insider buying this week. so i'm going to tell you now that the quag food market is closed i won't bump into you there. but i'm going to tell you i think it's worth a speculative bet. but i'm not making an investment call there, speculative bet. sal in new york, sal. reerl . >> caller: thanks for taking my call. congratulations on your ten-year anniversary. jim, i have been accumulating bank of america shares for quite a while. and still buying on dips. i would like your long and short-term view of bank of america given the backdrop of the tres test results, currency issue, and future interest rates. >> i was disit.ed by bank of america and the stress.

i've been disappointed about bank of america, both the stock and the company. i think that they are, if you want to put an order to it, i used to think citigroup, i used to think that citi was worse than bank of america. i no longer feel that way. i really prefer wells fargo, wfc. i don't think you should buy any more bank of america here. it's a wells fargo moment. that is the way to play it. all right, sure i expect some positive reports, but all i'm saying issing -- and i haven't said it in a long time but the market is really up huge this week. i don't want you to be greedy. i do want you to raise a little cash, because complacency post that fed meet, it seems to be everywhere. "mad money" tonight, it's like the chipotle for pizza with the twist and the stiek is popping hot, soaring 20% just this week. a name you probably never heard of until tonight. i'm going to reveal it. and nike has put some points on the board today. can he keep dominating the court? i'm going to lace up and find out. plus a new biotech serves what

could be game-changing news for a very terrible disease, parkinson's. stick with cramer. >> don't miss a second of "mad money" follow@jimcramer on twitter. send jim an e-mail to madmoney@cnbc.com or give us a call at 1-800-743-cnbc.

'. >> what the heck has been going on with papa murphy's. relatively quick serve take and bake pizza change. many of you have probably never heard of it. here's a tiny speculative $280 million company with a $16 and change stock that has been absolutely on fire of late. rallying 42% this year alone. and up a staggering 22% just over the past week. thanks in part to a terrific quarter reported on tuesday. that's a gigantic move, the kind you expect from a biotech stock,

not a pizza chain. also thoub to be fair, domino's has given us monumental long-term gains since i started recommending it five years ago. but what about pap murphy's. who thought you could make this kind of money in a irish pizza company? is this move for real. can it be trusted? does the stock have more room to run? it's speculation friday. we know the whole restaurant cohort has been roaring, thanks to the massive decline in the price of gasoline which gives the average american household an extra $1,000 worth of discretionary income per year out of nowhere. some of which they're definitely spending on dining out. we saw that this morning with the fabulous quarter out of darden the parent company of olive garden which caused the stock to spice almost 34%.

however, this is actually a unique story, benefitting from the increasing allure of natural and organic offerings. think about the whole chapter in get rich carefully, especially among the younger generation. so what exactly sets papa murphy's apart from papa john's. a couple of papas. papa murphy has a bizarre, at least to me but popular model. you go into a papa murphy's they prepare a pizza right in front of you. so far so good right? and then they take that uncooked pizza and they give it to you. that's right, you pak it at home. hence take and bake. this company is the largest take and bake pizza chain in the united states. and the fifth largest overall pizza chain with 1,461 locations across 38 state, along with canada, and, of course the united arab emirates. because they don't need to shell out for ovens or delivery people, papa murphy's has a lot less overhead which means they can sell their pizzas at a much lore price point.

but if you're planning on getting takeout, it doesn't get any more fresh than cooking the darn pizza at home. but even with the whole idea of take and bake pizza doesn't appeal to you, the fact is papa murphy's has a clear idea of who its target demographic is moms millosevicl millilials. they're number one for quality, speed of service, value freshness and politeness of employees. and according to ndp group, the company ha consistently been ranked number one year after year in taste, freshness, food quality and speed of service. where is papa murphy's been all my life? so we know papa murphys has a good product. on top of that, they also invested in terrific deck nolg which we know is necessary for quick serve restaurants to stay relative and keep their customers. papa murphys has point of sale interfaces at 77% of the stores

and if they get that number up to 100% over this year and the next. plus they're using targetsed mobile coupons to bring more people into the scores. at the end of the day, though we know this concept is working because of the numbers. remember papa murphys reported on tuesday st. patrick's day, and their domestic same-store sales decreased by 8.4r%. company-owned stores up extraordinary 10.5 a couple points better than the franchises. those are fabulous numbers. however, the real reason i'm excited about this speculative stock, the reason i devoted a whole segment to it is because of the growth opportunity. like i told you, papa murphys has 1,461 locations in the latest quarter. they opened 38 stores. and for full year 2015 they plan to increase 110 to 115 locations. we're talking nearly 8% new store growth with over 90% of those being franchises. that's not bad. but get this. long term pop la murphys believes they can increase their

footprint from 1,500 locations to a roughly an astounding 4,500 locations just in the u.s. this company plans to triple its store count. triple! is that actually a viable plan or is it a pipe dream? well, take a look at this map. the areas in orange are the states where the company has a high level of penetration. the areas in lighter orange show where it has stores but a lower level of penetration. and the area in green, they don't have any stores at all. that's the northeast, which is why many of you may have never heard of papa murph. now, papa murphys believes they can open another 2,500 stores just in their low density areas like the south, the midwest, the southwest and california. on top of that they think they can open 604 stores in the northeast, which to me seems like kind of a low ball estimate given that we're talking about some of the most densely populated areas in the country. either way you get to the 4,500

store threshold. and that would be be, wow, that would be super growth. i think it's the company's ability to increase its store count that has attracted so many investors to papa murphys. money managers absolutely salivate. whenever you see a turbo charged growth story in the restaurant base that's based on franchises you have to do a deeper dive. many restaurants have gone wrong by aggressively putting up new franchises regardless of whether or not it made sense. and then squeezing the franchises for money until the whole thing collapses. however, i don't think papa murphys is one of those stories. the franchisees are doing well. in some places papa murphys has seen the average weekly sales of its existing stores increase when they open up more locations. perhaps because it raises awareness for the overall brand. no cannibalization here. also they find their most successful franchises and buying

them out. they picked up six stores in the seattle area for $4 million with more of these deals likely to come. their company-owned stores tend to grow faster and better than the franchises do. so yes, i think papa mur firs is a viable even exciting company. what about the stock? after its recent run, papa murphys now trades at 26 times next year's earnings estimate. that puts it exactly on part with domino's and papa john's. however, it has much faster growth than its competitors. in other words, i think there's a good case to be made here that papa murphys deserves its premium price to earnings multiple. that said, it's an ultra speculative small cap stock, which means you should only ever buy it into weakness and always always always use limit orders or you will get burned. when i say speculative, you need to only use mad money, not borrowed money ira money, your kid's tuition money.

so here's the bottom line. yes, the recent run does make sense. this is a novel and successful concept that still has a lot of room to grow. but it's also extremely speculative, so please be careful. do not chase. maybe get a market wide pullback. build your position using limit orders. and then what i want you to do i want you to go bake a murph pizza and let me know how it tastes at jim cramer on twitter. much more "mad money" ahead including my take on the king of sportswear. then a biotech game soaring off of what could be huge news for parkinson's suffererers. plus, an entire group of names pretty much going up in a straight line. listen up, what i think you should do with biotech. it may surprise you. stick with cramer.

a tour deforce on why this is a must own senior growth stock. i got to tell you, it was a starter. the conference call was a dud. you felt so great about nike you could overlook any weakness and embrace any strength. first nike did what everyone should have done this quarter, just tell the story on a constant currency basis. nike is a worldwide company, it's obvious it's got head winds all over the place as the dollar has become almost cartoonish in its strength. so nike took the bull by its horns or at least the bullish dollar and said you factor it in. we're not going to do that much about it. we're not going to explain it. it's not our fault. even when the company shifted business with different venues they didn't take the bait. the impact instead of the call being one explanation of weakness after another, which is what happens when you translate things back, you could use the call to figure out just how strong nike really is. and recognize that the franchise is totally on sale no matter

where it completes. the essence of the call was we compete, we win, you figure out the currency. i don't know if-- oracle embraced a similar strategy earlier in the week and it was clearly winning. when you compare these two calls with ibm's, for instance, where you thought that ibm had simply done horrendously because it talked about actual currency compared to constant currency you realize the nike/oracle method is the way for companies to go, take out currency from the equation. but boy, there were other parts that i love. one of the crucial elements of the script was the insistence that all speakers use the phrase sustainable profit growth. this is another trend that the experts of the conference call use, including the chief financial officer of our parent comcast, as well as the former ceo of ford motor. you love these three terms bundled in one phrase. you know the companies that only go for growth for growth's sake they've fall completely out of

favor. you know the companies that give you growth less profits, you know the kind of growth profits that a cereal company gives, we don't want those anymore. we want real profits and real growth. nike doesn't want to be lumped in with consumer packaged goods names. they have to reject that. nike must be concerned about this issue because it's one of the great household names like coca-cola or kellogg, but unlike them, it does have real growth and nike doesn't want to seem episodic in if its growth as though it manufactures high-priced branded discretionary goods that will be cut out in any economic downturn. you couldn't pull this claim off if you were weak in we canner areas like china or brazil, but nike did just fine in those difficult regions. they could walk the walk and talk the talk about secular growth as opposed to cyclical choppyiness choppiness. i love how they handled the west coast port slowdown saying there's so many crates to be

offloaded. they just stated it. they learned the hazards of how william sonoma addressed the port concern and had some people backing away from it instead of really how well the company could have done without the port slowdown. and nike stressed innovation in technology, as well as its athletic-branded merchandise, namely kobes and jordans. oh, man, it resonated. so did its acknowledgment that it answers to the athlete, which is an interesting discernment from under ar miles an hour who doesn't stress the performance athlete now as much as the health and fitness buff. of course, there's room for both although one senior -- nike -- and lower risk than the more nun juror higher risk -- under ar miles an hour. let me give you the bottom line. nike had a tour deforce congratulations gentlemen first quarter with strong growth everywhere and an apology for an excellent running shoe number they highlighted as a disappointment that i didn't think was bad at all. nike

nike, what a bunch of pros. what an amazing stock. let's go to rick in florida, please. rick? >> caller: hi jim. my question is with nike and tsw and footlocker doing so well i wonder if it was time to go to finish line. >> i think you're totally right to think that. last quarter, finish line didn't do well. they report next week. i do not have my hopes up. as a matter of fact, i regard them in the penalty box. but it makes -- i know exactly what you're thinking but it hasn't translated before. let's go to jean in my home state of pennsylvania. >> caller: how are you? thanks for taking my call. >> of course. how are you? >> caller: i'm great. i'm a first-time caller. my husband and i watch your show all the time. a couple of months back you recommended lulu lemon. i love the brand, wear their clothes, i do yoga. they have a lot of new colors and it's gone up 20 points or

more than 20 points since you recommended it. my to you is should we buy some more hold or sell? >> great question. i know that jack moore, the researcher of my fund, they are reporting next week. i think the port situation could hurt the quarter. i'm betting a lot of people are betting against lulu because of the port situation. that means you might get a terrific chance a moment to do some buy buy, buy and that's what you should. i think that stock goes much higher precisely because of why you wear it. i think yoga is taking the world by storm and lulu lemon has its game back. nike's quarter, what a slam dunk. what a bunch of pros. what an incredible stock. nike, just do it. much more "mad money" ahead including a stock that jumped 32% today after releasing some very early stage but promising data on its parkinson's drug. most of biotech has been rocketing higher. what i'm going to recommend you do tonight might surprise you.

plus a look back at the week that was and a fantastic friday edition of "the lightning round." stick with cramer. ♪ ♪ ♪ (under loud music) this is the place. ♪ ♪ ♪ their beard salve is made from ♪ ♪ ♪ sustainable tea tree oil and kale... you, my friend, recognize when a trend has reached critical mass. yes, when others focus on one thing you see what's coming next. you see opportunity. that's what a type e does. and so it begins. with e*trade's investing insights center, you can spot trends before they become trendy. e*trade. opportunity is everywhere.

>> the brieioteches have been on fire. remember we did that big block of shows? well, all of them are up anywhere between 28 to 132% since mid january. this point, i think it might be time to actually start thinking about ringing the register if you haven't already. taking some profit take a little off the table. but i still think these names are worth highlights these red hot companies which is why tonight we need to focus on prta. that's a development stage biotech for diseases driven by protein misfolding or cell adhesion. this is tough stuff. more than $9 today or 32% in wake of terrific data on its first human study on prx 002. it's been working on with russia to treat parkinson's disease, an area where there's a huge unmet

medical disease. i mean wow. plus the company also has a formulation in phase one to treat amaldosis, which you may have heard on every episode of "alice." if you also own prothena i think you're a tad greedy if you haven't taken a little something off the table. that being said i wouldn't be surprised if this keeps running. let's speak to the president and ceo of prothena. welcome to "mad money." >> thank you very much. doctor tell me first, this is a terrible disease. my father had it. i know as soon as i heard parkinson's, i knew there's nothing out there. i don't want to get people's hopes up but it does sound like you have something early on that could be very meaningful for parkinson's people? >> well, exactly. as it turns out, you know parkinson's, as you mentioned, and sorry to hear about your father. but there are a number of very good treatments to deal with the symptoms currently, but there's

nothing to deal with the progression of the disease. and prx 002 we believe is the beginning of a wave or a new concept to go after the progression of the disease. it turns out that at the core of the disease is a protein or a gene called sanuclea. it's the bad actor in the disease. and it tends to aggregate nerve cells and cause them to dysfunction. and so what we've done is to develop a protein immunotherapy or antibody to go after sunuclea. and what we just reported are the phase one data from that initial study. we looked at safety and toll rablt -- tell. it seems to be safe and well tolerated. we also looked at the ability to the antibody to target neutral

neutralized sunuclea in the blood and it nicely reduced it to levels down 96% after just a single dose, which is, of course, a big result. we're very pleased -- go ahead. >> how many people were in the study? >> we had about 40 people in the study. these are healthy volunteers. so a decent sized study to assess the safety and the toler tolerability. >> people are getting their hopes up like i had my hopes up. i want to impress upon people, this is phase one. it's early op. no matter on it's not like we're going to see this on the market, even if everything goes right, next year at this time. >> yeah. it is phase one. ir'm glad you pointed that out. it is early. as you know there's three faces of clinical testing and, in fact, there's not a -- you know

there's not a hard timetable. i can't see exactly at this month and day when it would be available if all goes well. but even as early as it is as i mentioned to you, this is a sort of very new approach. and it's actually the same conceptual approach that was just announced with biogen for their therapy. the idea is to go after the culprit, the protein, in this case the synuclein. and we're targeting it and neutralizing it nicely. go ahead. >> your partner is russia -- roche. you have a lot of money already raised. obviously, you could do a secondary or whatever but do you feel like you have enough fire power to be able to complete the study without having to go raise a lot of money or have roche make a deal with you where the upside might be cut you have off? >> absolutely. we're very well capitalized.

we reported the end of last year $294 million the balance of the year. roche is very, very committed, a great partner, to see this through. so there's absolutely no concerns in 245 regard. it's full steam ahead. we have another study on going where it's in parkinson's patients, a multiple dose study that's literally under way right now. we're going to get a lot more information from that study as well. we'll be talking about that particular next study next year. so, you know we hope to come back and share with the community our progress in this area. we are indeed very excited about it. >> it sounds like you should be. and i hope you continue to share with us, having just watched what parkinson's can do anything that anybody could come up with would really be urgent. thank you so much dr. dale schenk, the president of prothena corporation. good to see you, sir. >> thank you very much. take care.

>> these are very early stage. this is very, very speculative. so i mean take your time. do some work on it. please get comfortable if you want to buy it. but understand the unmet need of parkinson's is pretty extraordinary. "mad money" is back after the break.

>> it is time for "the lightning round." you give me the stock and i tell you whether to buy, buy, buy or sell, sell sell. when you hear this sound it will be over. are you ready? tim. >> caller: love your show. i want to ask you a question about achlillion pharmaceutical. is it worth the price? >> no. we kind of learned that there's just too much competition now i don't think anyone is going to buy that company. if they do it won't be at a huge premium. david in new jersey. david? >> caller: hey, jim. new jersey boo-yeah! celedon. >> pretty good spec.

a lot of different compounds. i'm willing to go for it. 52-week high got to be careful. jeff in california. jeff? >> jim cramer, what's up? jeff from new port beach. what's your thoughts on sirius? >> it's a play on cars. i think it's doing a pretty good job. i like the last quarter. ree ghan montana. >> caller: jim, boo-yeah. my stock is dupont. two questions for you. one, what is your opinion on the company and two, do you think nelson will be successful. >> my opinion of the company is it's too high if nelson peltz isn't successful and if he is successful it can go higher. i do no not think that peltz will win because the stock moved too much. but i think nelson is trying to get things to be as good as possible. i think they should put him on the board. don in virginia.

>> caller: hey, jim, how you doing? boo-yeah. yeah, i got a question about shane digital. >> they had new games. look, it's an interesting play. i mean if it's gaming i'm always going to go to take two interactive. david in texas. david? >> caller: hi, jim. how you doing today? >> very well, how about you? >> caller: i'm doing good. i'm calling about virgin america. >> they're okay. remember the pecking order. southwest, because they never lost money. spirit air, and then we like american. aal. those are our triad. jennifer in idaho. jennifer? >> caller: mr. cramer what's going on with whole foods? >> whole foods is good. it's really starting to really gain strength again. i really like it. they're doing a lot right. and i like this level to buy whole foods. one more. let's go to mark in texas. mark? >> yeah. jim, the stock is vmv health

care. >> it's at a 52-week high. an amazing performer. that's a great stock. and that, ladies and gentlemen, is the conclusion of "the lightning round." >> all call me 1-800 743-cnbc or tweet me at -- let me start again. let me start again. i would like to start that again. [ bleep ] i never do that. >> big boo-yeah from sunny san diego. >> leslie in florida. leslie, let's go to john in california. john. >> caller: we need rain. if you have some water or snow we'll take it. >> i have some water, but i don't think it will do the job. those people they call in on "mad money" and say hey, jim.

i'm out here in santa monica. i want to say to them, you know how i feel? march madness, it has arrived. all this week march madness kicking off, we've been doing our own "mad money" version of bracketology. i am not going to be denied. talk about home court advantage. there.

>> what you're about to hear is not a sell. it's a don't buy call. you should feel free to interpret as a sell call if you want. for the last two weeks, i've been telling you two things. buy biogen into the data about the alzheimer's and cholesterol drugs respectively. i've been marveling at how these stocks go up on data that everyone in the know already expected. i said that come this friday i don't want you buying the stocks anymore, and i'm sticking by this. why? first of all i think the smart money could run you over with their profit taking maybe as early as next week. second the speculatives juices are flowing too heavily. just like they did last year at this time.

that ended badly for the best of the best in the group. no one got hurt taking a profit. so if you want to ring the register, i'm giving you my blessing. because i never mind people taking some money off the table to go by a cashmere sweater as my late mom did whenever she won at the ponies or the slots. mom was a very disciplined gambler. so why not dump them all? because i believe in them. i'm not going to go sell sell sell. these are the great drug companies about her era. i wrote about them endlessly in "get rich carefully" and in the e book, what do i say? repeat after this. i said celgene, biogen those are the four horsemen of the big pharma apocalypse. i'm not telling you cell, cell, cell. these have gone up let's say almost in a straight line. and that's the caveat i want you

to focus on. almost. when they do have their downturns, and they do, they are severe and ugly and you really don't want to buy them before those downturns. it's like yesterday. i wrote on twitter at jam cramer that everyone who complained about my recommendation of isis pharmaceutical are saying they paid the top price because it did slip down after that. listen to me, you're now up on your position. it hit an all-time high today. you're free to sell. if only so you don't blame me for any losses that you might incur. i tire of being accused of getting it wrong when thankfully, i really got this right. and i'm telling you, i don't want you to be greedy. look, i know these stocks if can still go higher and many will but i also don't want to hear, you cut me out of the next 100 points in biogen. but can i just stress, don't you think the easy -- can't you agree with me? don't you think the easy money has been made? i pressed my bet hard here over

and over again. when i pressed my bet repeatedly, i opened myself to a possible round trip or the loss of some hard-fought gain which is something i don't want to do. remember, again, a year ago the bet pressers in this group got their heads handed to them. i like where my head is located right now. i don't want you to be greedy. yes, the regeneron data is amazing. yes, biogen seems to have hit a rock 'em sock 'em alzheimer's drug. yes, the isis formulation, all 13 of them are very exciting. yes, i believe in receptos. yes, i like the future of immunotherapy. nevertheless, i love profits. i love making money. and a lot of money has been made. why not ring the register on some so you can try to play with some of the house's money? and not just your own. the bottom line no one has ever made a mistake taking a fat profit in the ten years i've been doing this show.

and if you buy them here and you blame me then you are sorely wrong and have lost all focus. focus bag code word for you're a real chowder head. stay with cramer. attention investors!s! vectorvest mobile is here and it's free! make faster, smarter better trading decisions with ctorvest mobile. the most powerful app or managing your portfolio from the palm of your hand. only vectorvest mobile analyzes ranks and graphs... ...over 16,000 stocks worldwide, everyday,... ...and gives you clear buy, sell, hold recommendations... ...on every stock; anytime, anywhere. vectorvest mobile comes free with your vectorvest trial. get it now! visit vectorvest.com/mobile to get started

>> looking over the file i just want to say, this stock is up 88% for the year. look at last year at this time for bioteches like prta and you'll see they all went down rather dramatically. it just happened. every one of them a lot of equity offerings. the stocks got very heavy and people said to me jim, why didn't you tell me to take something off the table? and that's what i was doing tonight. not telling you you have to sell everything, but just reminding you that last year at this time what a selloff. i would like to say there's always a bull market somewhere. i promise to try to find it just for you right here on "mad money." i'm jim cramer. i'll see you monday.

>> a high-tech control room. >> he is looking at everything that's going on here. >> railroad cars hauling urgent cargo. >> get it into a railcar as fast as we can. >> on a mission to create the world's most popular brew. >> we have a presence in over 80 countries. >> it's a cultural icon -- a bubbling legend. >> probably the most recognized beer label in the world. >> an ultimate beer from the ultimate factory -- budweiser.